Amalgamated Financial’s Akebia Therapeutics AKBA Stock Holding History

Amalgamated Financial’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$17K	Buy	+24,241	New	+$51.9K	﹤0.01%	2782

Other funds holding AKBA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

OCM

Orchard Capital Management Chicago, Illinois $95.9M AUM 45.49% 1-Year Est. Return

Amalgamated Financial's AKBA Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Akebia Therapeutics (AKBA) in Q1 2022: 24,241 shares worth $17K. The stake represents ﹤0.01% of the portfolio and ranks #2782 among its holdings.

124 funds tracked by Wall St. Rank hold AKBA as of Q1 2022.

Amalgamated Financial held 24,241 shares of Akebia Therapeutics worth $17K as of Q1 2022.
Akebia Therapeutics was a new Amalgamated Financial position in Q1 2022.
Akebia Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2782 holding.
124 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.